Table 1.
Baseline characteristics of CIBMTR and EBMT cohorts of lymphoma patients undergoing haploidentical related donor or 8/8 matched unrelated donor transplantation
| Haploidentical, N (%) |
Matched unrelated, N (%) | ||
|---|---|---|---|
| Variable | N (%) | N (%) | p-valuea |
| Number of recipients | 1830 | 310 | |
| Number of centers | 277 | 103 | |
| Recipient age at transplant | <0.001 | ||
| 18–29 years | 429 (23) | 45 (15) | |
| 30–39 years | 316 (17) | 48 (15) | |
| 40–49 years | 298 (16) | 40 (13) | |
| 50–59 years | 443 (24) | 89 (29) | |
| 60 years and older | 344 (19) | 88 (28) | |
| Median (Range) | 46 (18–71) | 53 (19–71) | <0.001 |
| Sex | 0.07 | ||
| Male | 1169 (64) | 214 (69) | |
| Female | 660 (36) | 95 (31) | |
| missing | 1 (<1) | 1 (<1) | |
| Karnofsky performance score | 0.09 | ||
| 90–100 | 1282 (70) | 200 (65) | |
| 10–80 | 497 (27) | 103 (33) | |
| Missing | 51 (3) | 7 (2) | |
| HCT-CI | <0.001 | ||
| <=2 | 1050 (57) | 157 (51) | |
| >2 | 362 (20) | 94 (30) | |
| missing | 418 (23) | 59 (19) | |
| Lymphoma subtype | <0.001 | ||
| Follicular Lymphoma | 137 (7) | 31 (10) | |
| DLBCL | 447 (24) | 75 (24) | |
| Mantle cell Lymphoma | 178 (10) | 53 (17) | |
| Classical Hodgkin lymphoma | 805 (44) | 86 (28) | |
| T-cell lymphoma | 263 (14) | 65 (21) | |
| NHL Disease status prior to HCT | 0.54 | ||
| Complete remission | 535 (52) | 122 (54) | |
| Partial remission | 317 (31) | 61 (27) | |
| Chemoresistant | 173 (17) | 41 (18) | |
| HD Disease status prior to HCT | 0.07 | ||
| Complete remission | 397 (49) | 52 (60) | |
| Partial remission | 264 (33) | 18 (21) | |
| Chemoresistant | 144 (18) | 16 (19) | |
| Prior auto-HCT | 0.05 | ||
| No | 736 (40) | 143 (46) | |
| Yes | 1094 (60) | 167 (54) | |
| Graft type | <0.001 | ||
| Marrow | 741 (40) | 27 (9) | |
| PBSC | 1089 (60) | 283 (91) | |
| Conditioning regimen intensity | 0.23 | ||
| Myeloablative | 415 (23) | 80 (26) | |
| Non-myeloablative/RIC | 1415 (77) | 230 (74) | |
| GVHD prophylaxis | <0.001 | ||
| PTCy + CNI + MMF | 1647 (90) | 167 (54) | |
| PTCy + othersc | 183 (10) | 143 (46) | |
| Time from diagnosis to HCT, months | |||
| Median (Range) | 29 (3–421) | 32 (3–369) | 0.88 |
| N Eval | 1822 | 309 | |
| Donor age | <0.001 | ||
| Less than 20 years | 112 (6) | 13 (4) | |
| 20–29 years | 392 (21) | 155 (50) | |
| 30–39 years | 423 (23) | 68 (22) | |
| 40–49 years | 307 (17) | 30 (10) | |
| 50+ years | 402 (22) | 7 (2) | |
| Missing | 194 (11) | 37 (12) | |
| Median (Range) | 37 (12–76) | 28 (18–55) | <0.001 |
| Donor/recipient sex match | <0.001 | ||
| Male-to-male | 706 (39) | 166 (54) | |
| Male-to-female | 341 (19) | 55 (18) | |
| Female-to-male | 461 (25) | 44 (14) | |
| Female-to-female | 317 (17) | 39 (13) | |
| Missing | 5 (<1) | 6 (2) | |
| Donor/recipient CMV match status | <0.001 | ||
| Donor +/ recipient + | 843 (46) | 95 (31) | |
| Donor +/ recipient − | 228 (12) | 36 (12) | |
| Donor – / recipient + | 310 (17) | 77 (25) | |
| Donor − / recipient − | 406 (22) | 94 (30) | |
| Missing | 43 (2) | 8 (3) | |
| Year of transplant | 0.002 | ||
| 2010–2014 | 529 (29) | 63 (20) | |
| 2015–2019 | 1301 (71) | 247 (80) | |
| Follow-up among survivors, Months | |||
| N Eval | 1146 | 231 | |
| Median (25th-75th quartiles) | 33 (14–55) | 21 (12–35) | <0.001 |
Abbreviations: CIBMTR, center for international blood and marrow research; EBMT, European Society for Blood and Marrow Transplantation; KPS, Karnofsky performance score; HCT hematopoietic cell transplantation; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; RIC, reduced intensity conditioning; GVHD, graft-versus-host disease; PTCy, post-transplant cyclophosphamide; CNI, calcineurin inhibitors; MMF, mycophenolate; CMV, cytomegalovirus
The Pearson chi-square test was used for comparing discrete variables; the Kruskal-Wallis test was used for comparing continuous variables
evaluable patients in haploidentical group = 1146 and MUD group = 231
PTCy + others: CNI only, sirolimus, methotrexate